Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (562)	2/3/2004 11:32:20 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 598

Well, I gotta mention that someone whose money I care about recently said he wanted to buy more tlrk. And I said oooooo, not now, better to wait. It was at $19 then, but $17 isn't all that much better. T67 is most definitely bothersome....As Rick says Goeddel certainly knows it better than anyone but we can be sure he didn't hold back any good data that was available. Further, there is still the nagging strategic justification that it was advanced, in part, in order to have an advanced clinical candidate on which to rest one of a couple eventual financings--which they really needed at the time p3 was announced. And dox is not without activity. T67 worries me plenty. But my fear factor has been rising overall, as I'm at 20% cash and going up. As for my calls, everyone is killing me in the contest. Since I have not had time to keep up with my own pack of mongrels, I've forgotten why I own half of them--a sure road to future losses. Will have to do the annual spring review soon. Until then I am on the no call list.